133 related articles for article (PubMed ID: 33861883)
1. Cutaneous delayed hypersensitivity from anakinra - The importance of clinical suspicion and skin testing.
Alen Coutinho I; Saraiva AP; Cunha F; Luís M; Todo Bom A
Contact Dermatitis; 2021 Sep; 85(3):381-382. PubMed ID: 33861883
[No Abstract] [Full Text] [Related]
2. Successful rapid subcutaneous desensitization to anakinra in a case of delayed-type hypersensitivity reaction.
Leroy V; Lazaro E; Darrigade AS; Taïeb A; Milpied B; Seneschal J
Br J Dermatol; 2016 Jun; 174(6):1417-8. PubMed ID: 26852184
[No Abstract] [Full Text] [Related]
3. Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adult-onset Still's disease.
Vordenbäumen S; Ostendorf B; Sander O; Richter J; Schneider M
Ann Rheum Dis; 2009 Mar; 68(3):450-1. PubMed ID: 19213754
[No Abstract] [Full Text] [Related]
4. [Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra].
Diallo A; Mekinian A; Boukari L; Mouas H; Zamy M; Nahon P; Gérin M; Fain O
Rev Med Interne; 2013 Mar; 34(3):168-70. PubMed ID: 23182291
[TBL] [Abstract][Full Text] [Related]
5. Is exogenous administration of IL-1ra (anakinra) likely to induce severe depression?
Jonville-Bera AP; Guilmot JL; Aspe G; Autret-Leca E; Magnant J
Eur J Clin Pharmacol; 2011 Feb; 67(2):213-4. PubMed ID: 20941485
[No Abstract] [Full Text] [Related]
6. Cardiac death in a patient with adult-onset Still's disease treated with the interleukin 1 receptor inhibitor anakinra.
Ruiz PJ; Masliah E; Doherty TA; Quach A; Firestein GS
Ann Rheum Dis; 2007 Mar; 66(3):422-3. PubMed ID: 17179171
[No Abstract] [Full Text] [Related]
7. Two cases of anakinra-induced neutropenia during auto-inflammatory diseases: drug reintroduction can be successful.
Perrin F; Néel A; Graveleau J; Ruellan AL; Masseau A; Hamidou M
Presse Med; 2014 Mar; 43(3):319-21. PubMed ID: 24456697
[No Abstract] [Full Text] [Related]
8. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report.
Guignard S; Dien G; Dougados M
Clin Exp Rheumatol; 2007; 25(5):758-9. PubMed ID: 18078628
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.
Laskari K; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2011 Jun; 13(3):R91. PubMed ID: 21682863
[TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy.
Ladhari C; Jorgensen C; Pers YM
Rheumatology (Oxford); 2019 Apr; 58(4):736-737. PubMed ID: 30590753
[No Abstract] [Full Text] [Related]
11. Efficacy of anakinra in a case of refractory Still disease.
Debiais S; Maillot F; Luca L; Buret J; Fautrel B; Renard JP
J Clin Rheumatol; 2008 Dec; 14(6):357-8. PubMed ID: 19033875
[No Abstract] [Full Text] [Related]
12. Subacute liver failure following anakinra treatment for adult-onset Still disease.
Aly L; Iking-Konert C; Quaas A; Benten D
J Rheumatol; 2013 Oct; 40(10):1775-7. PubMed ID: 24085761
[No Abstract] [Full Text] [Related]
13. Cardiac magnetic resonance in myocarditis from adult onset Still's disease successfully treated with anakinra.
Choi AD; Moles V; Fuisz A; Weissman G
Int J Cardiol; 2014; 172(1):e225-7. PubMed ID: 24461482
[No Abstract] [Full Text] [Related]
14. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease.
Yilmaz S; Cinar M; Simsek I; Erdem H; Pay S
Mod Rheumatol; 2014 Nov; 24(6):1030-1. PubMed ID: 24313885
[No Abstract] [Full Text] [Related]
15. Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.
Campochiaro C; Farina N; Tomelleri A; De Luca G; Cavalli G; Dagna L
Clin Exp Rheumatol; 2022 Sep; 40(8):1598-1599. PubMed ID: 35349406
[No Abstract] [Full Text] [Related]
16. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
Saper VE; Ombrello MJ; Tremoulet AH; Montero-Martin G; Prahalad S; Canna S; Shimizu C; Deutsch G; Tan SY; Remmers EF; Monos D; Hahn T; Phadke OK; Cassidy E; Ferguson I; Mallajosyula V; Xu J; Rosa Duque JS; Chua GT; Ghosh D; Szymanski AM; Rubin D; Burns JC; Tian L; Fernandez-Vina MA; Mellins ED; Hollenbach JA; ;
Ann Rheum Dis; 2022 Mar; 81(3):406-415. PubMed ID: 34789453
[TBL] [Abstract][Full Text] [Related]
17. Anakinra for the treatment of adult-onset Still's disease.
Castañeda S; Atienza-Mateo B; Martín-Varillas JL; Serra López-Matencio JM; González-Gay MA
Expert Rev Clin Immunol; 2018 Dec; 14(12):979-992. PubMed ID: 30324816
[TBL] [Abstract][Full Text] [Related]
18. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
19. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
20. Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra.
Raffeiner B; Botsios C; Dinarello C; Ometto F; Punzi L; Ramonda R
Joint Bone Spine; 2011 Jan; 78(1):100-1. PubMed ID: 21036649
[No Abstract] [Full Text] [Related]
[Next] [New Search]
